Altium Capital Management LP Inhibikase Therapeutics, Inc. Transaction History

Altium Capital Management LP

  • $177 Million
  • Q1 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
SELL
$1.79 - $2.81 $196,450 - $308,394
-109,749 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$2.8 - $6.23 $307,297 - $683,736
109,749 New
109,749 $307,000

Others Institutions Holding IKT

# of Institutions
2
Shares Held
1.03M
Call Options Held
0
Put Options Held
0
View Full List

About Inhibikase Therapeutics, Inc.

IKT Quotes by TradingView
  • Ticker IKT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,227,100
  • Market Cap $33.8M
  • Description
  • Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...
More about IKT
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email